Quick Take
Harmony Biosciences Holdings (HRMY) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is a biopharma commercializing its WAKIX molecule for the treatment of excessive sleepiness in adult narcolepsy.
HRMY has initially grown revenue quickly as it begins to commercialize its primary product.
I’ll provide an update when we learn more about the IPO from management.
Company & Technology
Plymouth Meeting, Pennsylvania-based Harmony was founded to commercialize a drug to treat narcolepsy that is not scheduled as a